Clinical trials rebound after COVID-19 setbacks, and early treatment leads to significant reduction in anal cancer risk among people with HIV.

by Thomas Celona

Patients who lose weight through bariatric surgery have a lower cancer risk, and a HER2-targeted therapy gets striking results in HER2-low breast cancer patients.

by Kevin McLaughlin

Contrast dye shortage delays scans for cancer, and more public assistance linked to higher survival rates for Black cancer patients.

by Eric Fitzsimmons

A blood test could help determine who benefits from checkpoint inhibitors in lung cancer, and the FDA approves a drug combination for certain patients with acute myeloid leukemia.

by Marci A. Landsmann

Esophageal cancer increases in the middle-aged, and adolescent and young adult leukemia survivors face continued mortality risk after treatment ends.

by Eric Fitzsimmons

First child to receive CAR T-cell therapy celebrates 10 years cancer-free, and authorization denials delay treatment for patients with Medicare Advantage.

by Marci A. Landsmann

Adolescents and young adult cancer survivors at higher risk for dying from a new cancer diagnosis, and FDA grants full approval to Enhertu for metastatic HER2-postive breast cancer.

by Eric Fitzsimmons

FDA proposes ban on menthol cigarettes, and proton beam therapy on the rise but with growing racial disparity.

by Thomas Celona

Study finds a connection between bacteria and fast-growing prostate cancer, and researchers measure underrepresentation of Black patients in clinical trials.

by Kevin McLaughlin

Trial of ‘practice-changing’ immunotherapy yields positive results for lung cancer patients, and CAR T-cell therapy shows effectiveness in targeting certain solid tumors.

by Thomas Celona